Plasma therapy may not reduce the risk of serious illness or deaths from COVID-19. A new study has finds this information.

Plasma is taken from the blood of a person who has been dehydrated. The person makes antibodies, which can fight off the virus. If the plasma of a disease-free person is applied to the body of a sick person, it is thought that the antibody may also fight the virus in the recipient’s body.

Plasma therapy is also being used in several countries to treat patients infected with the coronavirus. Although the effectiveness of therapy, in this case, is not yet completely certain.

Several countries, including India and the United States, have urgently approved the use of this convoluted plasma. There are several clinical trials going on to see if it really works. One of his new studies conducted across India. The results were published in the medical journal British Medical Journal (BMJ).

This convoluted plasma has been shown to be ‘slightly effective’ against coronaviruses, the research article said.

However, researchers say that future studies could only use plasma that contains high levels of inactive antibodies. It remains to be seen whether plasma is more effective in preventing corona.

So far, there is no cure for coronavirus. There is no effective vaccine to prevent corona. As a result, various countries are looking for ways to reduce the severity of the virus in the body. Part of this is the use of plasma therapy.

Plasma therapy was first used against diphtheria in 1892. In addition, plasma therapy has recently been shown to be effective in the rapid recovery of people infected with Ebola and SARS viruses. The coronavirus is responsible for Covid-19, which belongs to the same family.

Recently some observational studies have been conducted on the treatment of coronavirus. From them, the researchers speculated that plasma therapy could be beneficial against the virus.

But this new study has been conducted in a clinical trial method. Patients are selected on a random basis from various government and private hospitals across India.

The average age of the 464 patients who took part in the study, funded by the Indian Council of Medical Research, was 52 years. Researchers have found that convulsive plasma is not able to reduce mortality.